JP2002504090A - 液体調合物における安定な粒子 - Google Patents

液体調合物における安定な粒子

Info

Publication number
JP2002504090A
JP2002504090A JP54026298A JP54026298A JP2002504090A JP 2002504090 A JP2002504090 A JP 2002504090A JP 54026298 A JP54026298 A JP 54026298A JP 54026298 A JP54026298 A JP 54026298A JP 2002504090 A JP2002504090 A JP 2002504090A
Authority
JP
Japan
Prior art keywords
formulation
aqueous
microparticles
phase
continuous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP54026298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002504090A5 (cg-RX-API-DMAC7.html
Inventor
ヤープ カムピンガ
Original Assignee
クアドラント ホールディングス ケンブリッジ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10809442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2002504090(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by クアドラント ホールディングス ケンブリッジ リミテッド filed Critical クアドラント ホールディングス ケンブリッジ リミテッド
Publication of JP2002504090A publication Critical patent/JP2002504090A/ja
Publication of JP2002504090A5 publication Critical patent/JP2002504090A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP54026298A 1997-03-18 1998-03-18 液体調合物における安定な粒子 Ceased JP2002504090A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9705588.3A GB9705588D0 (en) 1997-03-18 1997-03-18 Stable particle in liquid formulations
GB9705588.3 1997-03-18
PCT/GB1998/000817 WO1998041188A2 (en) 1997-03-18 1998-03-18 Stable particle in liquid formulations

Publications (2)

Publication Number Publication Date
JP2002504090A true JP2002504090A (ja) 2002-02-05
JP2002504090A5 JP2002504090A5 (cg-RX-API-DMAC7.html) 2005-11-10

Family

ID=10809442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54026298A Ceased JP2002504090A (ja) 1997-03-18 1998-03-18 液体調合物における安定な粒子

Country Status (14)

Country Link
US (1) US6669963B1 (cg-RX-API-DMAC7.html)
EP (1) EP1007000B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002504090A (cg-RX-API-DMAC7.html)
CN (1) CN1256626A (cg-RX-API-DMAC7.html)
AT (1) ATE325605T1 (cg-RX-API-DMAC7.html)
AU (1) AU722627B2 (cg-RX-API-DMAC7.html)
BR (1) BR9808920A (cg-RX-API-DMAC7.html)
CA (1) CA2293682C (cg-RX-API-DMAC7.html)
DE (1) DE69834495T2 (cg-RX-API-DMAC7.html)
EA (1) EA001873B1 (cg-RX-API-DMAC7.html)
GB (1) GB9705588D0 (cg-RX-API-DMAC7.html)
NO (1) NO994508L (cg-RX-API-DMAC7.html)
NZ (1) NZ337666A (cg-RX-API-DMAC7.html)
WO (1) WO1998041188A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510156A (ja) * 2005-10-04 2009-03-12 ケンブリッジ バイオスタビリティ リミテッド ガラス状粒子中で安定化した医薬組成物
JP2011514337A (ja) * 2008-02-25 2011-05-06 ノババックス,インコーポレイテッド 糖ガラス化ウィルス様粒子(vlp)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ88697A3 (en) 1994-09-22 1997-09-17 Quadrant Holdings Cambridge Composition used for re-hydration and nourishment in the course of athletic outputs and processes for preparing thereof
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
WO1999047174A1 (en) * 1998-03-18 1999-09-23 Cambridge Biostability Limited Amorphous glasses for stabilising sensitive products
US6190701B1 (en) 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
US6102896A (en) * 1999-09-08 2000-08-15 Cambridge Biostability Limited Disposable injector device
DE19943491B4 (de) * 1999-09-10 2010-04-01 Südzucker AG Mannheim/Ochsenfurt Verbesserte Komprimate
WO2001037804A2 (en) * 1999-11-22 2001-05-31 Universal Preservation Technologies, Inc. Preservation and formulation of bioactive materials
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
GB0024271D0 (en) * 2000-09-25 2000-11-15 Colaco Camilo Improved methods and compositions for pulmonary delivery of actives
AU1198601A (en) * 2000-10-13 2002-04-29 Cambridge Biostability Ltd Composition and method for stable injectable liquids
EP1449523A1 (en) * 2000-10-13 2004-08-25 Cambridge Biostability Ltd Composition and method for stable injectable liquids
RU2259817C2 (ru) * 2000-10-13 2005-09-10 Кембридж Байостэбилити Лтд. Композиция для доставки стабильных инъецируемых жидкостей и способ доставки
WO2002032398A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for drug delivery
US7153472B1 (en) 2000-11-22 2006-12-26 Quadrant Drug Delivery Limited Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
US6623762B2 (en) * 2001-02-16 2003-09-23 Cambridge Biostability Ltd. Composition and method for controlled release injections
FR2825276B1 (fr) * 2001-05-31 2004-11-26 Seppic Sa Adujvant d'immunite sous forme solide et vaccin le contenant
US20040197885A1 (en) * 2001-07-02 2004-10-07 Shigeru Ueda Method of stabilizing alkaline phosphatase
US7799765B2 (en) * 2001-08-10 2010-09-21 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Association compound of trehalose or maltitol with metal ion compound
GB2379390B (en) 2001-09-11 2005-01-26 Caretek Medical Ltd A novel drug delivery technology
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
US20060045891A1 (en) * 2004-08-24 2006-03-02 Lovalenti Phillip M Density-matched suspension vehicles and pharmaceutical suspensions
US20060142630A1 (en) * 2004-12-29 2006-06-29 Attila Meretei Systems and methods for treating a thrombus in a blood vessel
US7515971B1 (en) * 2005-09-09 2009-04-07 Pacesetter, Inc. Left atrial pressure sensor lead
GB0523638D0 (en) 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
US8946200B2 (en) 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
DE102006056790B3 (de) * 2006-12-01 2008-01-17 IfP Privates Institut für Produktqualität GmbH Laboreinmalartikel für Analyse und Diagnosik
EP1930396B1 (de) * 2006-12-04 2011-07-06 Merck Patent GmbH Furochromanderivate
WO2008092084A2 (en) * 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
LT2170279T (lt) * 2007-07-31 2018-03-12 Otsuka Pharmaceutical Co., Ltd. Aripiprazolo suspensijos ir liofilizuotos kompozicijos gamybos būdai
US8404850B2 (en) 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
US8722706B2 (en) 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
WO2011007327A2 (en) * 2009-07-16 2011-01-20 Koninklijke Philips Electronics N.V. Suspension for therapeutic use and device for delivering said suspension
US8293299B2 (en) 2009-09-11 2012-10-23 Kraft Foods Global Brands Llc Containers and methods for dispensing multiple doses of a concentrated liquid, and shelf stable Concentrated liquids
CN102115737B (zh) * 2009-12-31 2015-06-03 深圳迈瑞生物医疗电子股份有限公司 稳定碱性磷酸酶或其标记物的试剂和方法
US9028873B2 (en) 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
CN102269762B (zh) 2010-06-04 2014-12-10 深圳迈瑞生物医疗电子股份有限公司 结合物的制备方法及相关试剂盒
CN102269761A (zh) 2010-06-04 2011-12-07 深圳迈瑞生物医疗电子股份有限公司 一种碱性磷酸酶结合物的合成工艺
US8512679B2 (en) 2011-03-04 2013-08-20 Elwha Llc Glassy compositions
JP6114278B2 (ja) 2011-09-09 2017-04-12 クラフト・フーヅ・グループ・ブランヅ リミテッド ライアビリティ カンパニー 常温保存可能な淹出飲料濃縮物、及びそれを調製する方法
BR112014009866A2 (pt) 2011-10-25 2018-09-04 Onclave Therapeutics Limited formulações de anticorpos e métodos
US11013248B2 (en) 2012-05-25 2021-05-25 Kraft Foods Group Brands Llc Shelf stable, concentrated, liquid flavorings and methods of preparing beverages with the concentrated liquid flavorings
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
RU2726030C2 (ru) 2014-07-03 2020-07-08 Крафт Фудс Груп Брэндс Ллк Концентраты с низким содержанием воды для приготовления кофейных и чайных напитков и способы их получения
CN111558046A (zh) * 2020-05-27 2020-08-21 华润昂德生物药业有限公司 海藻糖在制备重组人促红素液体制剂中的应用及重组人促红素液体制剂、制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031255A (en) * 1975-07-03 1977-06-21 General Foods Corporation Fixing acetaldehyde in sucrose
US3970765A (en) * 1975-07-03 1976-07-20 General Foods Corporation Method for producing sucrose fixed volatile flavors
GB1490814A (en) * 1975-07-22 1977-11-02 Cadbury Ltd Heat-resistant chocolate product and method of manufacturing same
JPS562908A (en) * 1979-06-20 1981-01-13 Nikken Kagaku Kk Preparation of stable live bacterial pharmaceutical remedy
DE3484584D1 (de) * 1983-10-14 1991-06-20 Sumitomo Pharma Injektionen mit verzoegerter abgabe.
WO1989003671A1 (fr) * 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Preparation a liberation entretenue
US5250429A (en) * 1991-09-20 1993-10-05 Pharmacia P-L Biochemicals Inc. Glassified restriction enzymes
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
ATE252373T1 (de) 1994-08-04 2003-11-15 Elan Drug Delivery Ltd Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5593824A (en) * 1994-09-02 1997-01-14 Pharmacia Biotech, Inc. Biological reagent spheres
GB9508691D0 (en) * 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
CN1245957C (zh) 1995-06-07 2006-03-22 廓德伦特控股剑桥有限公司 将物质稳定掺入干燥泡沫玻璃基质中的方法以及由此制得的组合物
US5762961A (en) 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5958455A (en) 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US5766520A (en) 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510156A (ja) * 2005-10-04 2009-03-12 ケンブリッジ バイオスタビリティ リミテッド ガラス状粒子中で安定化した医薬組成物
JP2011514337A (ja) * 2008-02-25 2011-05-06 ノババックス,インコーポレイテッド 糖ガラス化ウィルス様粒子(vlp)

Also Published As

Publication number Publication date
NO994508L (no) 1999-11-17
CN1256626A (zh) 2000-06-14
NZ337666A (en) 2001-04-27
EP1007000B1 (en) 2006-05-10
WO1998041188A3 (en) 1998-12-10
AU722627B2 (en) 2000-08-10
EA001873B1 (ru) 2001-10-22
EA199900835A1 (ru) 2000-04-24
AU6510198A (en) 1998-10-12
DE69834495D1 (de) 2006-06-14
NO994508D0 (no) 1999-09-17
GB9705588D0 (en) 1997-05-07
BR9808920A (pt) 2000-08-01
EP1007000A2 (en) 2000-06-14
ATE325605T1 (de) 2006-06-15
US6669963B1 (en) 2003-12-30
WO1998041188A2 (en) 1998-09-24
DE69834495T2 (de) 2006-09-07
CA2293682A1 (en) 1998-09-24
CA2293682C (en) 2007-01-16

Similar Documents

Publication Publication Date Title
EP1007000B1 (en) Stable particle in liquid formulations
CA2264776C (en) Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity
AU2004277419B2 (en) Nanoparticulate therapeutic biologically active agents
JP2000514811A (ja) タンパク質医薬の持続送達のための温度感受性ゲル
HK1210720A1 (en) Technology for preparation of macromolecular microspheres
KR20070037444A (ko) 고체 미립자성 치료제의 생체외 적용방법
CA2565296A1 (en) Sustained-release microspheres and methods of making and using same
CA2424656C (en) Composition and method for stable injectable liquids
AU2001211986A1 (en) Composition and method for stable injectable liquids
JP2003507388A (ja) 凍結乾燥したケーキの安定化
US6586011B2 (en) Microencapsulated plasminogen activators
AU2005203369B2 (en) Pharmaceutical liquid suspensions
JP4027881B2 (ja) 安定注射液用の組成物および方法
EP1452171B1 (en) Pharmaceutical liquid suspensions
JP4382706B2 (ja) 医薬液体懸濁物
CN100594937C (zh) 稳定的注射液组合物和方法
KR100743442B1 (ko) 약제적 액체 현탁액
RU2259817C2 (ru) Композиция для доставки стабильных инъецируемых жидкостей и способ доставки
EA050946B1 (ru) ЛИОФИЛИЗИРОВАННЫЕ ПРЕПАРАТЫ мРНК, АДСОРБИРОВАННОЙ НА ЛИПИДНЫХ ЧАСТИЦАХ НАНОЭМУЛЬСИИ
NZ538681A (en) A pharmaceutical composition comprising active biological ingredient carried by particles that form a stable suspension in a liquid indefinitely

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050318

A72 Notification of change in name of applicant

Free format text: JAPANESE INTERMEDIATE CODE: A721

Effective date: 20081002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091006

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100217

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20120925